Wogonin inhibits IL-6-induced angiogenesis via down-regulation of VEGF and VEGFR-1, not VEGFR-2

被引:32
|
作者
Lin, Chiu-Mei
Chang, Hang
Chen, Yeh-Hsu
Wu, I-Hsing
Chiu, Jen-Hwey
机构
[1] Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei 112, Taiwan
[2] Shin Kong Wu Ho Su Mem Hosp, Dept Emergency Med, Taipei, Taiwan
[3] Taipei City Hosp, Taipei, Taiwan
[4] Taipei Med Univ, Coll Med, Taipei, Taiwan
[5] Vet Gen Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan
[6] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan
[7] Vet Gen Hosp, Res Ctr Tradit Chinese Med, Taipei, Taiwan
关键词
wogonin; angiogenesis; IL-6; IL-6R; VEGF; VEGFR-1;
D O I
10.1055/s-2006-951692
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
So far, no antiangiogenic activity of wogonin, a flavonoid, on human umbilical vein enclothelial cells (HUVECs) has been demonstrated. The aim of this study was to investigate the effects of wogonin on IL-6-induced angiogenesis in HUVEC cultures and chorioallantoic membrane (CAM) neovascularization. The in vivo CAM model was applied to evaluate the percentage of new vessel formations, followed by measurement of endothelial migration and tube formation in HUVEC cultures. The results revealed that wogonin (10-8-10-5M) concentration-dependently
引用
收藏
页码:1305 / 1310
页数:6
相关论文
共 50 条
  • [1] Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1
    Lin, Chiu-Mei
    Chang, Hang
    Chen, Yeh-Hsu
    Li, Shih Yun
    Wu, I-Hsing
    Chiu, Jen-Hwey
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2006, 6 (11) : 1690 - 1698
  • [2] Chrysin inhibits lipopolysaccharide-induced angiogenesis via down-regulation of VEGF/VEGFR2(KDR) and IL-6/IL-6R pathways
    Lin, Chiu-Mei
    Chang, Hang
    Li, Shih-Yun
    Wu, I-Hsing
    Chiu, Jen-Hwey
    PLANTA MEDICA, 2006, 72 (08) : 708 - 714
  • [3] Glioma cells enhance endothelial progenitor cell angiogenesis via VEGFR-2, not VEGFR-1
    Zhang, Junxia
    Zhao, Peng
    Fu, Zhen
    Chen, Xiaolei
    Liu, Ning
    Lu, Ailin
    Li, Rui
    Shi, Lei
    Pu, Peiyu
    Kang, Chunsheng
    You, Yongping
    ONCOLOGY REPORTS, 2008, 20 (06) : 1457 - 1463
  • [4] Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
    Nascimento, Catarina
    Gameiro, Andreia
    Ferreira, Joao
    Correia, Jorge
    Ferreira, Fernando
    CANCERS, 2021, 13 (01)
  • [5] Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma
    Dales, JP
    Garcia, S
    Bonnier, P
    Duffaud, F
    Carpentier, S
    Djemli, A
    Ramuz, O
    Andrac, L
    Lavaut, M
    Allasia, C
    Charpin, C
    ANNALES DE PATHOLOGIE, 2003, 23 (04) : 297 - 305
  • [6] Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR)
    El-Obeid, A
    Sunnuqrut, N
    Hussain, A
    Al-Hussein, K
    Gutiérrez, MI
    Bhatia, K
    LEUKEMIA RESEARCH, 2004, 28 (02) : 133 - 137
  • [7] Chrysin Suppresses IL-6-Induced Angiogenesis via Down-regulation of JAK1/STAT3 and VEGF: An in Vitro and in Ovo Approach
    Lin, Chiu-Me
    Shyu, Kou-Gi
    Wang, Bao-Wei
    Chang, Hang
    Chen, Yen-Hsu
    Chiu, Jen-Hwey
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2010, 58 (11) : 7082 - 7087
  • [8] Ultrastructure and histomorphometric analysis of human umbilical cord vessels in preeclampsia: a potential role of VEGF, VEGFR-1 and VEGFR-2
    Almasry, Shaima M.
    Elfayomy, Amr K.
    Hashem, Hala E.
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2016, 57 (02) : 681 - 689
  • [9] VEGF, VEGFR-1 and VEGFR-2 immunoreactivity in the porcine arteries of vascular subovarian plexus (VSP) during the estrous cycle
    Postek, A
    Andronowska, A
    Doboszynska, T
    Nieweglowski, H
    Jankowska, K
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2006, 44 (01) : 17 - 23
  • [10] Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
    Dziobck, Konrad
    Oplawski, Marcin
    Grabarek, Benjamin Oskar
    Zmarzly, Nikola
    Tomala, Barbara
    Halski, Tomasz
    Lesniak, Ewa
    Januszyk, Krzysztof
    Brus, Ryszard
    Kielbasinski, Robert
    Boron, Dariusz
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2019, 20 (11) : 955 - 963